D. Straus

发表

Extranodal MALT Lymphoma of the Right Triceps Muscle following Influenza Vaccine Injection: A Rare Case with an Interesting Presentation

E. Athanasian, J. Yahalom, S. Edwards-Bennett, 2011, ISRN hematology.

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma

A. Zelenetz, J. Glassman, J. Bertino, 1999, Bone Marrow Transplantation.

Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations.

B. Clarkson, J. Gaynor, J. Ryu, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, New England Journal of Medicine.

Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.

P. Maslak, Z. Fuks, J. Yahalom, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.

B. Clarkson, J. Gaynor, D. Merke, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results and prognostic factors following optimal treatment of advanced Hodgkin's disease.

B. Clarkson, J. Gaynor, D. Merke, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

J. Gabrilove, J. Bertino, P. Hamlin, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.

D. Leung, J. Yahalom, C. Portlock, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

L. Jacks, J. Yahalom, A. Noy, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA

V. Seshan, S. Horwitz, J. Gerecitano, 2017 .

The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.

L. Norton, J. Bertino, J. Yahalom, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA

K. Savage, H. Schoder, A. Dogan, 2023, Hematological Oncology.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, The New England journal of medicine.